AXL and non-small cell lung carcinoma: Significant OS disadvantages were observed for the NSCLC metastasis patients with high AXL expression (AXLHigh), high GAS6 expression (GAS6High), and N 2/3 stage (P < 0.01), compared with the AXLLow, GAS6Low, N 0/1 stage group, respectively (Fig. 3a–c).